UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here’s Why

1 month ago 21

Noor Ul Ain Rehman

Tue, February 10, 2026 astatine 5:41 AM CST 2 min read

Royalty Pharma Plc (NASDAQ:RPRX) is 1 of the champion healthcare stocks nether $50 to put in. On January 30, Royalty Pharma Plc (NASDAQ:RPRX) was upgraded to Buy from Neutral by UBS, with the steadfast raising the terms people connected the banal to $49 from $38. The steadfast told investors that Royalty Pharma Plc (NASDAQ:RPRX) has delivered a bid of charismatic royalty deals, “meaningfully” bolstering its maturation profile. UBS sees a “catalyst-rich” 2026 for the company, with the imaginable of driving “significant banal upside connected upcoming de-risking events.”

Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now?

It added that Royalty Pharma Plc (NASDAQ:RPRX) has an charismatic maturation illustration connected some an implicit and comparative ground compared to respective large-cap pharma names experiencing worldly nonaccomplishment of exclusivities.

In summation to UBS, Citi besides lifted the terms people connected Royalty Pharma Plc (NASDAQ:RPRX) to $50 from $48 connected January 27, maintaining a Buy standing and adjusting terms targets successful the biopharma radical arsenic portion of a fiscal Q4 preview. According to the firm, factors specified arsenic “beatable” estimates and reduced argumentation hazard should make a favorable setup for the radical successful 2026.

Royalty Pharma Plc (NASDAQ:RPRX) funds innovation successful the biopharmaceutical manufacture and buys biopharmaceutical royalties. It collaborates with innovators from probe hospitals, non-profits, and world institutions done tiny and mid-cap biotech companies to planetary pharma companies. The institution funds innovation successful the manufacture some directly, by partnering with companies to co-fund late-stage objective trials and caller merchandise launches successful speech for aboriginal royalties, and indirectly, by acquiring existing royalties from the archetypal innovators.

While we admit the imaginable of RPRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.